Skip to main content

Treatment Clinical Trials for Rectal Cancer

Review the rectal cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 45

Testing Chemotherapy versus Chemotherapy plus Radiotherapy Prior to Limited Surgery for Early Rectal Cancer
Status: Active
Location: 76 locations
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Status: Active
Location: 15 locations
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Status: Active
Location: 13 locations
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Status: Active
Location: 14 locations
Botensilimab and Balstilimab before Standard Chemotherapy for the Treatment of Mismatch Repair Proficient Rectal Cancer
Status: Active
Location: 7 locations
A Study of Tucatinib and Trastuzumab in Patients with HER2-Positive Locally Advanced Rectal Cancer
Status: Active
Location: 7 locations
Evaluate REC-4881 in Patients With FAP
Status: Active
Location: 6 locations
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Status: Active
Location: 6 locations
Chemoradiation with Combination Chemotherapy for the Treatment of Rectal Cancer
Status: Active
Location: 5 locations
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Status: Active
Location: 6 locations
Chemotherapy (mFOLFOX) and Short-Course Radiotherapy for the Treatment of Resectable Rectal Cancer
Status: Active
Location: 3 locations
Standard Chemotherapy and Short or Long Course Radiation Therapy with or without BMX-001 for the Treatment of Stage II-III Rectal Cancer
Status: Active
Location: 3 locations
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Status: Active
Location: 3 locations
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Status: Active
Location: 3 locations
Papaverine in Combination with Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
Status: Active
Location: 7 locations
Epacadostat with Standard Chemoradiation Therapy before Surgery in Treating Patients with Locally Advanced Rectal Cancer
Status: Active
Location: 2 locations
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Status: Active
Location: 5 locations
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination with Standard of Care Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
Status: Active
Location: 2 locations
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
No Surgery Trial / Two Dose-escalation Strategies
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
AMB-05X for Treating Patients with ctDNA(+) Stage I-IV Colorectal Cancer after Curative-Intent Treatment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Inhalational or Intravenous Anesthesia during Surgery for Patients with Colon Cancer, VIVA Study
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Microsatellite Stable Localized Rectal Cancer before Surgery
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
ctDNA-Directed Chemotherapy after Hepatectomy for the Treatment of Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Avutometinib, Defactinib and Cetuximab for the Treatment of Patients with Unresectable or Metastatic, Refractory Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas